Pulmonary Embolism News and Research

RSS
A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.
Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

EKOS receives $2.7M grant to develop product for treatment of ICH

EKOS receives $2.7M grant to develop product for treatment of ICH

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene reports initial data from investigator-initiated study of REVLIMID

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Stanford Hospital & Clinics uses endovascular laser technology to retrieve permanently embedded IVC filters

Stanford Hospital & Clinics uses endovascular laser technology to retrieve permanently embedded IVC filters

US District Court dismisses all claims and counterclaims in thalidomide patent cases

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Statins may play role in lowering risk of clot-related diseases: Study

Statins may play role in lowering risk of clot-related diseases: Study

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Medtronic completes enrollment in first of two CURE-AF clinical trials

Medtronic completes enrollment in first of two CURE-AF clinical trials

New sensor wristband monitors various body functions

New sensor wristband monitors various body functions

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Men with prostate cancer may face increased risk of thromboembolism

Men with prostate cancer may face increased risk of thromboembolism

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.